Evaluation of a Pharmacist-Specific Intervention on 30-Day Readmission Rates for High-Risk Patients with Pneumonia

Overview

Journal Hosp Pharm

Publisher Sage Publications

Date 2016 Jan 30

PMID 26823619

Citations 6

Authors

Katelin M Lisenby

Douglas N Carroll

Nathan A Pinner

Affiliations

Soon will be listed here.

Abstract

Background: Pharmacist interventions have been shown to have an impact on reducing readmission rates, however further research is necessary to target resources to high-risk populations and determine the most effective bundle of interventions.

Objective: To evaluate the effect of a pharmacist-bundled intervention on 30-day readmission rates for high-risk patients with pneumonia.

Methods: A pilot study with a historical control conducted at a community, teaching-affiliated medical center. Up to 65 selected subjects were included if they had pneumonia and any of the following high-risk criteria: admission within 6 months, at least 5 scheduled home medications, chronic obstructive pulmonary disease (COPD), or heart failure. A retrospective chart review was conducted to compile the historical control group that received usual care between June and November 2013. Patients admitted from December 2013 through March 2014 were reviewed to receive a bundled intervention. The primary outcome was 30-day readmission rates. Risk factors and reasons for readmission, pharmacist clinical interventions, and the time interval between discharge and readmission were also evaluated.

Results: A trend toward a reduced 30-day readmission rate was observed in the intervention group (n = 43) compared to those who received usual care (n = 65) (27.9% vs 40.0%; relative risk [RR], 0.6977; 95% CI, 0.3965-1.2278; P = .2119). The most commonly identified high-risk inclusion criteria were having at least 5 scheduled home medications and COPD. The time interval between discharge and readmission did not considerably differ between groups (10.8 vs 10.6 days).

Conclusions: The pharmacist-bundled intervention was associated with a reduced 30-day readmission rate for high-risk patients with pneumonia.

Citing Articles

The impact of hospital-based post-discharge pharmacist medication review on patient clinical outcomes: A systematic review.

Costello J, Barras M, Foot H, Cottrell N Explor Res Clin Soc Pharm. 2023; 11:100305.

PMID: 37655116 PMC: 10466898. DOI: 10.1016/j.rcsop.2023.100305.

Multidimensional Interventions on Supporting Disease Management for Hospitalized Patients with Heart Failure: The Role of Clinical and Community Pharmacists.

Jasinska-Stroschein M, Waszyk-Nowaczyk M J Clin Med. 2023; 12(8).

PMID: 37109373 PMC: 10142526. DOI: 10.3390/jcm12083037.

Investigation of drug-related problems in patients hospitalized in chest disease wards: A randomized controlled trial.

Bektay M, Sancar M, Okyaltirik F, Durdu B, Izzettin F Front Pharmacol. 2023; 13:1049289.

PMID: 36703759 PMC: 9872030. DOI: 10.3389/fphar.2022.1049289.

Chronic Obstructive Pulmonary Disease Treatment and Pharmacist-Led Medication Management.

Li L, Han Y, Zhang Z, Zhou W, Fang H, Qu J Drug Des Devel Ther. 2021; 15:111-124.

PMID: 33469264 PMC: 7811374. DOI: 10.2147/DDDT.S286315.

Effect of clinical pharmacist encounters in the transitional care clinic on 30-day re-admissions: A retrospective study.

Borhanjoo P, Kouamo P, Rahman M, Norton M, Gavini M AIMS Public Health. 2019; 6(3):345-354.

PMID: 31637283 PMC: 6779605. DOI: 10.3934/publichealth.2019.3.345.

References

Jack B, Chetty V, Anthony D, Greenwald J, Sanchez G, Johnson A . A reengineered hospital discharge program to decrease rehospitalization: a randomized trial. Ann Intern Med. 2009; 150(3):178-87. PMC: 2738592. DOI: 10.7326/0003-4819-150-3-200902030-00007. View

Makaryus A, Friedman E . Patients' understanding of their treatment plans and diagnosis at discharge. Mayo Clin Proc. 2005; 80(8):991-4. DOI: 10.4065/80.8.991. View

Forster A, Murff H, Peterson J, Gandhi T, Bates D . Adverse drug events occurring following hospital discharge. J Gen Intern Med. 2005; 20(4):317-23. PMC: 1490089. DOI: 10.1111/j.1525-1497.2005.30390.x. View

Gleason K, McDaniel M, Feinglass J, Baker D, Lindquist L, Liss D . Results of the Medications at Transitions and Clinical Handoffs (MATCH) study: an analysis of medication reconciliation errors and risk factors at hospital admission. J Gen Intern Med. 2010; 25(5):441-7. PMC: 2855002. DOI: 10.1007/s11606-010-1256-6. View

Kirkham H, Clark B, Paynter J, Lewis G, Duncan I . The effect of a collaborative pharmacist-hospital care transition program on the likelihood of 30-day readmission. Am J Health Syst Pharm. 2014; 71(9):739-45. DOI: 10.2146/ajhp130457. View

Gattis W, Hasselblad V, Whellan D, OConnor C . Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study. Arch Intern Med. 1999; 159(16):1939-45. DOI: 10.1001/archinte.159.16.1939. View

Coleman E, Smith J, Raha D, Min S . Posthospital medication discrepancies: prevalence and contributing factors. Arch Intern Med. 2005; 165(16):1842-7. DOI: 10.1001/archinte.165.16.1842. View

Pal A, Babbott S, Wilkinson S . Can the targeted use of a discharge pharmacist significantly decrease 30-day readmissions?. Hosp Pharm. 2014; 48(5):380-8. PMC: 3839464. DOI: 10.1310/hpj4805-380. View

Gillespie U, Alassaad A, Henrohn D, Garmo H, Hammarlund-Udenaes M, Toss H . A comprehensive pharmacist intervention to reduce morbidity in patients 80 years or older: a randomized controlled trial. Arch Intern Med. 2009; 169(9):894-900. DOI: 10.1001/archinternmed.2009.71. View

10.

Budnitz D, Lovegrove M, Shehab N, Richards C . Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011; 365(21):2002-12. DOI: 10.1056/NEJMsa1103053. View

11.

Vinks T, Egberts T, de Lange T, De Koning F . Pharmacist-based medication review reduces potential drug-related problems in the elderly: the SMOG controlled trial. Drugs Aging. 2009; 26(2):123-33. DOI: 10.2165/0002512-200926020-00004. View

12.

Jencks S, Williams M, Coleman E . Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med. 2009; 360(14):1418-28. DOI: 10.1056/NEJMsa0803563. View

13.

Erickson J . The cost of medication noncompliance. AAPPO J. 1993; 3(2):33-4, 38-40. View

14.

Hansen L, Young R, Hinami K, Leung A, Williams M . Interventions to reduce 30-day rehospitalization: a systematic review. Ann Intern Med. 2011; 155(8):520-8. DOI: 10.7326/0003-4819-155-8-201110180-00008. View

15.

Davies E, Green C, Mottram D, Rowe P, Pirmohamed M . Emergency re-admissions to hospital due to adverse drug reactions within 1 year of the index admission. Br J Clin Pharmacol. 2010; 70(5):749-55. PMC: 2997315. DOI: 10.1111/j.1365-2125.2010.03751.x. View

16.

Greenwald J, Jack B . Preventing the preventable: reducing rehospitalizations through coordinated, patient-centered discharge processes. Prof Case Manag. 2009; 14(3):135-40. PMC: 2720804. DOI: 10.1097/NCM.0b013e318198d4e1. View

17.

Walker P, Bernstein S, Tucker Jones J, Piersma J, Kim H, Regal R . Impact of a pharmacist-facilitated hospital discharge program: a quasi-experimental study. Arch Intern Med. 2009; 169(21):2003-10. DOI: 10.1001/archinternmed.2009.398. View

18.

Koehler B, Richter K, Youngblood L, Cohen B, Prengler I, Cheng D . Reduction of 30-day postdischarge hospital readmission or emergency department (ED) visit rates in high-risk elderly medical patients through delivery of a targeted care bundle. J Hosp Med. 2009; 4(4):211-8. DOI: 10.1002/jhm.427. View

19.

Schnipper J, Kirwin J, Cotugno M, Wahlstrom S, Brown B, Tarvin E . Role of pharmacist counseling in preventing adverse drug events after hospitalization. Arch Intern Med. 2006; 166(5):565-71. DOI: 10.1001/archinte.166.5.565. View

20.

Leon A, Davis L, Kraemer H . The role and interpretation of pilot studies in clinical research. J Psychiatr Res. 2010; 45(5):626-9. PMC: 3081994. DOI: 10.1016/j.jpsychires.2010.10.008. View